ClinicalTrials.gg
CompletedNCT05224609Updated Aug 30, 2024

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

A Phase 1 interventional study of Lorlatinib in Moderate Hepatic Impairment, Severe Hepatic Impairment and Healthy Volunteers, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-30.

Sponsored by Pfizer · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Lorlatinib) in health participants. This study is seeking participants who:

  • Must be male or female of 18 to 75 years of age, inclusive at the time of the study.
  • Are willing and able to comply with all scheduled visits, treatment plan, and other study procedures.
  • Have a BMI (body mass index) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).
  • Are capable of giving signed informed consent document. All participants in this study will receive Lorlatinib. Participants will be placed into 1 of 3 cohorts based on their hepatic (liver) function. Participants will take Lorlatinib once by mouth. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective. Participants will take part in this study for up to 35 days.
Read the detailed description

This is a Phase 1, open label, parallel group study to investigate the effect of moderate and severe hepatic impairment on the plasma PK, safety, and tolerability after a single oral 100 mg dose of lorlatinib under fasted conditions.

02

Conditions studied

  • Moderate Hepatic Impairment
  • Severe Hepatic Impairment
  • Healthy Volunteers
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

All Participants -

  1. Participants must be male or female of 18 to 75 years of age, inclusive, at the time of signing the ICD.
  2. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  3. of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).
  4. Capable of giving signed as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Additional Inclusion Criteria for Participants with Normal Hepatic Function (Cohort 3) -

  1. Healthy is defined as no abnormalities identified by a detailed medical history, complete physical examination, including BP and pulse rate measurement, 12-lead or clinical laboratory tests. Particularly, should confirm no known or suspected hepatic impairment based on liver function tests (eg, , AST, ALP, and ), albumin and .
  2. Participants must fit the demographic-matching criteria, including: Body weight +- 15 kg of the median of the combined moderate and severe hepatic impairment cohorts (Cohorts 1 and 2), as provided by the sponsor.

Age +- 10 years of the median of the combined moderate and severe hepatic impairment cohorts (Cohorts 1 and 2), as provided by the sponsor.

Comparable male/female ratio to moderate and severe hepatic impairment cohorts (Cohorts 1 and 2).

Additional Inclusion Criteria for Participants with Moderately Impaired Hepatic Function (Cohort 1) -

  1. Meet the criteria for Class B (moderate hepatic impairment) of the modified classification.
  2. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver , hepatic ultrasound, computerized tomography scan, or MRI.
  3. Stable hepatic impairment, defined as no clinically significant known change in disease status within the last 30 days, as documented by the participant's recent medical history (eg, no worsening clinical signs of hepatic impairment, or no worsening of total bilirubin or prothrombin time by more than 50%).
  4. Stable drug regimen is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to the dosing of lorlatinib.
  5. History of alcohol abuse is permissible providing that the results of alcohol test are negative at Screening or on Day -1, and the participant is willing and able to abide by the lifestyle guidelines.

Additional Inclusion Criteria for Participants with Severely Impaired Hepatic Function (Cohort 2) -

  1. Meet the criteria for Class C (severe hepatic impairment) of the modified Child-Pugh classification.
  2. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, computerized tomography scan, or MRI.
  3. Stable hepatic impairment, defined as no clinically significant known change in disease status within the last 30 days, as documented by the participant's recent medical history (eg, no worsening clinical signs of hepatic impairment, or no worsening of TBili or prothrombin time by more than 50%).
  4. Stable drug regimen is defined as not starting a new drug or changing dosage within 7 days or 5 half lives (whichever is longer) prior to the dosing of lorlatinib.
  5. History of alcohol abuse is permissible providing that the results of alcohol test are negative on Screening or on Day -1, and the participant is willing and able to abide by the lifestyle guidelines.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

All Participants -

  1. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
  2. History of or current positive results for infection.
  3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic (eg. Contact with positive case, residence, or travel to an area with high incidence) that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  4. Participants with an of ≤ 60 mL/min/1.73 m2 based on the 2021 CKD-EPI equation, with a single repeat permitted to assess eligibility, if needed.
  5. Concurrent use of any of the following prohibited concomitant medication(s) within 12 days prior to the first dose of lorlatinib:

    1. Known strong inhibitors (eg, boceprevir, cobicistat, clarithromycin, conivaptan, diltiazem, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, tipranavir, troleandomycin, voriconazole, grapefruit juice or grapefruit/grapefruit-related citrus fruits [eg Seville oranges, pomelos]). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed.
    2. Known strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane, phenytoin, rifabutin, rifampin, St. John's Wort).
    3. Known P-gp substrates with a narrow therapeutic index (eg, digoxin).
  6. Concurrent use of CYP3A substrates with narrow therapeutic indices (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl including transdermal patch, pimozide, quinidine, sirolimus, tacrolimus) within 12 days prior to the first dose of lorlatinib.
  7. Previous administration with an drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
  8. Known to lorlatinib or its .
  9. A positive urine drug test. Participants with moderate or severe hepatic impairment (Cohorts 1 and 2) will be eligible to participate if their urine drug test is positive with a drug for a prescribed condition that is not expected to interfere with the PK of lorlatinib.
  10. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  11. History of sensitivity to heparin or heparin-induced thrombocytopenia.
  12. Unwilling or unable to comply with the criteria in the Lifestyle Considerations,
  13. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Additional Exclusion Criteria for Participants with Normal Hepatic Function (Cohort 3) -

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies deemed relevant for participation in this study, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
  3. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If initial supine BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  4. Baseline standard 12-lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline interval >450 msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree AV block, baseline PR interval >200, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be rate corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding a participant.
  5. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of ≤1 g/day. Limited use of nonprescription medications that are not believed to affect participant safety or the overall results of the study may be permitted on a case by case basis following approval by the Sponsor. Herbal supplements and HRT must have been discontinued at least 28 days prior to the dose of lorlatinib.
  6. Participants with a history of or current positive results for or , including HBsAg, HBcAb, or HCVAb.

Additional Exclusion Criteria for Participants with Moderate and Severe Hepatic Impairment (Cohorts 1 and 2) -

  1. Other clinically significant disease that contraindicates study drug or that may affect the PK of lorlatinib.
  2. Hepatic carcinoma and hepatorenal syndrome.
  3. Undergone porta-caval shunt surgery.
  4. History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than 1 month prior to study entry.
  5. Any clinically significant laboratory abnormality except for those parameters influenced by hepatic impairment.
  6. Presence of clinically active Stage 2, 3 or 4 encephalopathy.
  7. Severe uncontrolled ascites and/or pleural effusion.
  8. Screening supine BP ≥160 mm Hg (systolic) or ≥90 mm Hg (diastolic), on a single measurement following at least 5 minutes of rest. If initial supine BP is ≥160 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the three BP values should be used to determine the participant's eligibility.
  9. Screening supine 12-lead ECG demonstrating QTcF >470 msec. If initial QTcF exceeds 470 msec, the ECG should be repeated two more times and the average of the three QTcF values should be used to determine the participant's eligibility.
  10. Second-degree or third-degree AV block (unless paced) or baseline PR interval >200 msec at any time prior to dosing of study treatment.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Moderate hepatic impairment group

    Drug: Lorlatinib

  • Experimental
    Cohort 2

    Severe hepatic impairment group

    Drug: Lorlatinib

  • Experimental
    Cohort 3

    Normal hepatic function

    Drug: Lorlatinib

Interventions

  • Single 100mg oral dose anti-cancer agent

    Also known as: Lorbrena, PF-06463922

06

What researchers measure

Primary outcomes

  1. Single dose Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (inf)] of lorlatinib

    PK parameter of lorlatinib to be calculated from the plasma concentration time data.

    Time frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post-dose

  2. Single dose Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (last)] of lorlatinib

    PK parameter of lorlatinib to be calculated from the plasma concentration time data.

    Time frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post-dose

  3. Single dose Maximum Observed Plasma Concentration (Cmax) of lorlatinib

    Maximum lorlatinib plasma concentration observed during study.

    Time frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post-dose

Secondary outcomes

  1. Number of participants experienced treatment emergent adverse event assessed by investigator

    Type, incidence, severity, seriousness, and relationship to study medications of adverse events (AE)

    Time frame: Baseline up to Day 35

  2. Number of participants experienced treatment related adverse event assessed by investigator

    Type, incidence, severity, seriousness, and relationship to study medications of adverse events (AE)

    Time frame: Baseline up to Day 35

  3. Number of participants experienced serious adverse event assessed by investigator

    Type, incidence, severity, seriousness, and relationship to study medications of adverse events (AE)

    Time frame: Baseline up to Day 35

  4. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs (pulse, systolic and diastolic blood pressure) were obtained. Clinical significance of vital signs was determined at the investigator's discretion.

    Time frame: Baseline up to Day 35

  5. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

    Laboratory parameters included: hematology (hemoglobin, hematocrit, red blood cell count, MCV, MCH, MCHC, platelet count, white blood cell count, neutrophils, eosinophils, monocytes, basophils, and lymphocytes), chemistry (blood urea nitrogen, creatinine, glucose \[fasting\], calcium, sodium, potassium, chloride, bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, direct bilirubin, alkaline phosphatase, uric acid, albumin, and total protein). Clinical significance of laboratory parameters was determined at the investigator's discretion.

    Time frame: Baseline up to Day 8

  6. Number of participants with change from baseline and absolute values in QTcF meeting criteria of potential clinical concern

    Federicia corrected QT (QTcF) will be summarized using actual values and changes from baseline. The participants meeting criteria of potential clinical concern will be judged by investigator.

    Time frame: Baseline up to Day 12

07

Study locations

3 sites
  • Orange County Research Center
    Tustin, California 92780, United States
  • Genesis Clinical Research, LLC
    Tampa, Florida 33603, United States
  • Prism Research LLC dba Nucleus Network
    Saint Paul, Minnesota 55114, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Aug 2024, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2022
First posted
Feb 4, 2022
StartActual
Apr 28, 2022
Primary completionActual
Aug 13, 2024
CompletionActual
Aug 13, 2024
Last update
Aug 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05224609
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 4, 2022
Start date
Apr 28, 2022
Primary completion
Aug 13, 2024
Completion
Aug 13, 2024
Last update
Aug 30, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorlatinib

Start the discussion